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Case-control studies examining the effects of oral contraceptives (OC) are prone to 
misclassification bias due to errors in assessment of OC use. Concern about inaccurate exposure 
histories has increased since current studies require women to recall OC use over prolonged periods 
of time. In preparation for a case-control study of breast cancer and OC use, an investigation was 
carried out to assess agreement between women’s lifetime histories of OC use (covering a period of 
up to 20 years) and prescribers’ records. OC histories were obtained during personal interview with 
218 women who had used OC at some point in their lives (127 breast cancer patients, 91 controls). 
Recall was aided by an album with color photographs of all OC marketed in the Netherlands from 
1962 onwards (n=65), and a calendar that covered the women’s life span from date of birth to 
menopause. The participants were asked for the names of all physicians who prescribed OC for 
them. The rate of response from the prescribers was high &I%), but only half of the forms provided 
useful information. Patient-prescriber agreement on brand names (including dosage) was 70%. About 
half of the women agreed with their prescribers on starting dates to within less than a year’s 
difference. Approximately the same percentage of agreement was found for stopping dates. Multiple 
linear regression indicated that agreement on brand names and dates of usage was lower for women 
of low socioeconomic status, for healthy women (as compared to breast cancer patients) and for 
periods of pill use that had to be recalled from the more distant past. Agreement on total duration of 
use was high enough to permit testing of a moderately strong duration-response relationship in a 
case-control study. 
No epidemiologic study can be better than the quality of the raw data collected for analysis (1,2). 
Although this well-known statement is regarded as a generally accepted truth, it often tends to be 
forgotten in epidemiologic practice. This certainly holds true for case-control studies examining the 
effects of oral contraceptive (OC) use on breast cancer risk. Since the 1960’s, when OC came into 
widespread use, more than 30 such studies have been conducted of which all except one (3) relied 
totally on the memory of the woman for information about OC use. In more recent case-control 
studies,women had to recall OC use, including brand names, starting and stopping dates of each 
contraceptive pill taken, over a period of twenty years or more. Skegg reviewed the potential biases 
in the studies of breast cancer and OC conducted to date and, among others, expressed concern 
about bias arising from misclassification of exposure (4). In the absence of information on OC use 
from an independent source (e.g., physician records), inaccuracy of OC histories from the women 
mav lead to differential and/or undifferential misclassification. Nondifferential misclassification. 
mo.&ly resulting in a reduc& (“diluted”) relative risk estimate, is inevitable in any study using 
subjects’ information only (56). Differential misclassification may affect the relative risk estimate 
upward if breast cancer c&&. by looking for the possible causes of their disease, overestimate their 
duration of OC use as compared to controls (4). Although the separate and combined effects of 
differential and non-differential misclassification have not been assessed in any of the studies of OC 
use and breast cancer, other investigations addressed this issue. In several studies (7-lo), a 
Correspondence to : 
Flora E. van Leeuwen 
Department of Epidemiology 
The Netherlands Cancer Institute 
121 Plesmanlaan, 
1066 CX Amsterdam, The Netherlands 
Submittea for publication January 14, 1992 
Accepted for publication March 23, 1992 
Copyright Q 1992 Butterworth-Heinemann 
400 Contraception 
comparison of women’s contraceptive histories with physicians’ records was made. Unfortunately. 
these studies are of only limited value to the current discussion. Three of these studies (7-9) were 
conducted in the mid-seventies, and thus could not yield information about recall of prolonged 
periods of OC use. Two studies (7.10) were restricted to healthy women, thus rendering it impossible 
to assess differential misclassification. A recent case-control study in the UK examined specffically 
differential misclasstfication of duration of OC use. Such misclassification was found to be negligible 
(3). 
In the present study, we report on the extent of agreement between women’s recalled OC use and 
prescribers’ records. The study population consists of breast cancer cases and controls who 
participated in a pilot study to test data collection procedures for a case-control study of breast 
cancer and OC use in The Netherlands. From the comparison between OC histories of users and 
prescribers,we calculated the extent of misclassification bias to be expected in a case-control study. 
In addltion, we examined which characteristics of the women affected levels of agreement. 
The present studv was not oart of a case-control study of breast cancer and OC use, but 
specific&y addressed the feasibility and validity of data c6lection procedures for such a study. 
Therefore, eligibility criteria for cases and controls were chosen primarily on practical grounds and 
differed from the criteria employed in the actual case-contrd study. The study population consisted 
of 151 breast cancer cases and 93 healthy contrds. Cases were diagnosed with breast cancer in the 
Netherfands Cancer Institute (Antoni van Leeuwenhoek Hospital) between January 1990 and 
November 1985, who reported OC use for more than one month at some point in their lives and who 
were under 65 years of age. Interviews took place during the period January 1983 - January 1986. 
For 75% of the cases, the interview took place wlthin a year of diagnosis. Two control groups were 
used: friend controls (n=69) and hospital controls with a diagnosis of benign breast disease 5 years 
or more before time of interview (n=33). Like the cases, controls had some reported history of OC 
use and were younger than 65 years. 
Breast cancer cases and hospital controls were asked to participate in the study via an 
explanatory letter signed by their treating physician. Friend controls were selected by asking 60 
breast cancer patients for the name of a friend who had ever used the pill, who was about their age 
and who would be willing to participate. All women were told that the purpose of the study was to 
assess the accuracy of recalling prescribed drug use. 
Data Colk2ctton 
Information on OC use was collected via personal interviews conducted by six trained, female 
interviewers. Interviews took 30 minutes to 1 hour to complete. To help women in recalling the 
specific brand names and the starting and stopping dates of each contraceptive pill ever taken, two 
memory alds were used. First, an album was prepared with color photographs of all OC (both 
packages and pills) ever marketed in The Netherlands from 1962 onwards (65 preparations). Next to 
each photograph was indicated the period during which the preparation had been on the market. 
Second, a calendar was used that covered a woman’s Me span from date of birth to menopause. All 
reproductive and other life events that were considered to be helpful in recalling OC use were noted 
on this calendar. 
Women were asked for the names of all physicians and health care facilities that had prescribed 
their OC. All prescribers were sent an explanatory letter about the purpose of the study. A standard 
form was enclosed (with a stamped, self-addressed envelope), that requested prescribers to fill out 
specific brand names and starting and stopplng dates of all OC preparations used by the women 
concerned. Also enclosed was a form, signed by the woman, in which she gave us permission to ask 
prescribers for information about her OC use. Prescribers who did not respond initially were followed 
up with a maximum of two tdephone contacts. 
DataAnatvsiq 
Agreement of each woman’s history of OC use with that provided by her prescriber(s) was 
calculated for the following aspects of OC use: specific brand name (including dose), starting date, 
stopping date and duration of use. This was done for all OC combined and, separately, for the first, 
the latest and the second-latest OC used For women who used only one type of OC, this was 
regarded as her first and her latest OC. A second-latest OC was assumed only to exist for women 
who used more than two pills. Total duration of use was calculated by summing up the time periods 
between stopping date and starting date of each preparation used Extent of user/prescriber 
agreement regarding types of OC use (e.g. first used vs. last used) and subgroups of women were 
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tested for statistical 
since the number of 
significance with the chi+quare test. Chance agreement was not corrected for 
OC preparations on the market was high (n =65) and also varied by time period. 
Multiple linear regression analysis was carried out to examine whether agreement could be 
explained by characteristics of the women and by calendar period of OC use. The dependent 
variabfe in this analysis was dichotomous for agreement on brand name (agreement vs. no 
agreement), and was defined as the difference in months between user and prescriber for agreement 
on dates of usage. Given the dichotomous nature of the dependent variable for agreement on brand 
name, this analysis was also done employing discriminant function analysis. The two analytic 
approaches yielded equfvalent results. In the present report only results emanating from the multiple 
linear regression analysis will be shown. 
The effect of misclassfffcations in duration of use on the relative risk estimates in a hypothetical 
case-control stud 
Y 
was calculated according to Marshall et al. (6). For this calculation it Is necessary 
to assume that:a prescribers’ records are more valki than OC histories as recalled by the women 
themselvesand b) a duration-response relationship exists between OC use and breast cancer risk. 
Of a total of 151 breast cancer patients and 93 controls contacted, 134 cases (89%) and 91 
controls (98%) agreed to participate. The non-responders among the cases were all, except one, 
stage lllb and IV patients, who were already in a terminal phase of disease when approached for the 
interview. Seven interviews with cases coukl not be used for various reasons, such as lack of 
permission to contact the prescriber (2 cases), being one’s own prescriber (2 cases) and having 
contact with prescribers about OC use after having been asked to participate in the .study (3 cases). 
Thus, we were abfe to approach the prescribers of 218 women (I27 cases and 91 controls). Table 
I presents several characteristics of the study population. 
The median duration of OC use amounted to 8.1 years and one-third of the study population had 
started OC use more than 20 vears before the interview. No sianificant differences were oresent 
between breast cancer patients-and controls with respect to age ‘distribution and characteristics of 
OC use. The median age of cases and controls was 46.2 and 44.7 years, respectively (p = 0.46). 
Characteristics of women and their OC use in 
the study population (n=218) 
Characteristic % of oooulation Characteristic % of oooulation 
Study group 
Cases 
Controls 
58.3 
41.7 
Starting date 
before Julv 1965 33.1 
Julv ‘65 - h ‘70 42.2 
Age at interview 
c30 
31 - 40 
41 -45 
46 - 50 
51 -60 
61 -65 
4.7 
21.9 
21.4 
26.0 
July ‘70 - July ‘75 20.1 
after July ‘75 4.6 
22.3 
3.7 
Stopping date 
before July 1973 
July ‘73 - July ‘81 
after July ‘81 
still user in 1984/85 
24.2 
46.8 
23.7 
5.3 
Number of preparations used Total duration of use 
1 30.0 0 - 2 years 22.8 
2 36.4 2 - 6 years 21.6 
3 21.7 6 - 10 years 27.8 
>4 11.9 10 - 12 years 12.2 
> 12 years 15.6 
Prescriber’s msoonse 
The study population of 218 women reported a total of 598 periods of OC use. Prescriber 
response amounted to 93.6%, but the amount of information supplied varied substantially. 
tnformation on either brand name or date(s) of usage became available for only 46.1% of the 
periods of OC use mentioned by the women, Only for 33.6% of the recalled OC periods was 
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prescriber information complete. i.e. both the specific brand name, starting date and stopping date 
were mentioned. The main reason for unavailability of prescriber Information was retirement or death 
of the actual prescriber. In such cases, data on the patient’s OC use had not been forwarded onto 
the woman’s new physician. As a consequence, prescriber availability of OC information was lower 
for preparations first used than for preparations last used (24.8% vs 42.7%). Prescriber response did 
not vary significantly by case-control status or age group. 
Aoeementorlbrandnames 
fable II displays data on agreement between users and prescribers on formulation-specific brand 
names. For all women combined, agreement was higher (though not significantly so) for the latest 
OC used than for OC s used previously. When cases and controls were considered separately, 
however, agreement did not vary by sequence of use for the patients, whereas for the controls, 
agreement was lower for first and second-latest pill than for the most recent pill used (p < 0.10). 
Breast cancer patients showed higher agreement on brand names than controls, though the 
difference was not statistically significant (74% and 65% respectively; p = 0.17). 
Agreement of OC users with prescribers on specific brand name, by order of pill use and 
case/control status (in parentheses the number of OC s for which agreement could be calculated) 
OC characteristic % agreement 
cases controls total 
most recent OC used 75.0 (n=68) 72.7 (n=33) 74.3 (n= 101) 
second-latest OC used 76.5 (n=34) 50.0 (n=14) 66.8 (n=48) 
first OC used 74.5 (n=55) 58.3 (n= 24) 69.6 (n=79) 
all OC used 73.5 (n= 155) 64.9 (n=77) 70.7 (n=232) 
Aareementondateaofusaa 
Table Ill shows agreement between users and prescribers on starting and stopping dates. 
This table provides the cumulative percentages of agreement when agreement is defined as a 
difference of less than x months in dates as reported by OC user and prescriber (with x varying 
between 6 and 48). For example, 38.2% of OC users recalled a starting date of their first OC that was 
less than 6 months apart from the date recorded by the prescriber. 
Table Ill 
Agreement of OC users with prescribers on starting and stopping dates of the first and the most 
recent OC used 
Cumulative % aareement 
Agreement, defined 
as a user-orescriber 
difference’ 
of 
Starting dates of 
first most all 
oc recent OC 
Stopping dates of 
first most all 
oc recent OC 
(n=68) c82) (n=183) (n=54) KSS) (n=179) 
< 6 months 38.2 33.0 34.4 42.6 41.7 43.6 
5 12 months 52.9 469 47.0 48.2 62.9 53.7 
< 24 months 72.0 66.0 65.6 74. i 80.9 74.3 
< 48 months 85.2 84.3 85.3 88.9 95.5 91 .o 
> 48 months 100.0 100.0 100.0 100.0 100.0 100.0 
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Agreement on the starting date of the first OC used was sli 
for all other OC combined (p = 0.52). For stopping datesflable Ill 3 
htly higher as compared with that 
, agreement on the latest OC used 
showed higher agreement than that on other OC preparations $I = 0.09). Agreement on stopping 
date of the second-latest OC used showed a distribution similar to that of the first OC used (not 
shown). For a study of breast cancer and OC,we considered a user-prescrfber difference of less than 
12 months as acceptable. In general, about 50% of the women matched their prescriber within such 
a margin; only for the stopping date of the latest OC used was agreement over 66%. Breast cancer 
patients and controls showed very similar distributfons for agreement on starting and stopplng dates 
both of the first and the latest OC used (all p-values exceeding 0.80; not shown). 
ondumtkmdusq 
Agreement on total duration of use could be calculated only In those cases where we were 
able to obtain information from both user and prescriber on dates of usage of all OC used by one 
woman. This was achieved for only 44 women (33 cases and 11 controls). Agreement on total 
duratlon to wfthin 2 years, which we considered to be acceptable In an actual case-control study, 
was 59.1%. This percentage did not differ slgnkfcantly between breast cancer patients and controls 
(66.6% and 54.6%, respectively). 
Since the effect of dlfferent brands of OC on risk of disease may vary, duration of use per 
preparation Is also a useful measure In eoMemiofooic studies. Aareement on oreoaration-soecffic 
buratlon of use could be calculated for a mtrch large;sample than &al duration of use. As is shown 
InTable IV, about half of the women agreed with their prescribers to within one year. The percentage 
agreement for cases was slightly higher than for controls, but the dffference-was not .statisticaiy 
significant (p=O.34). 
Table IV 
Agreement of OC users with prescribers on preparation-specific duration of use, 
by case-control status 
Agreement 
defined as a 
user-prescriber 
difference 
of 
Cumulative % agreement 
cases controls total 
(n=105) (n=48) (n=153) 
< 6 months 38.1 27.1 34.6 
< 12 months 56.2 39.6 51 .o 
< 24 months 70.5 64.6 68.5 
< 46 months 87.6 87.5 87.5 
> 48 months loo.0 100.0 100.0 
In Table V we calculated the apparent relative risk estimates for a hypothetical case-control 
study exhibiting the same degree of misclassification In total duration of use as was found In the 
present study. As can be seen in the upper part of TableV the actual relative risk oradient in the 
hypothetical study Is assumed to result from ~lncreaslng duration of exposure among cases and a 
uniform level among controls. From the lower pan of Table V, it can be seen that the apparent 
relative risk gradient, though less steep than the actual one, Is clearty emerging. This is due to the 
fact that breast cancer patients and controls were about equally likely to overstate or understate their 
exposure. For both cases and controls, overstatement occurred much more frequently than 
understatement. We repeated the same calculations for the duration of the longest OC used since 
this information was avallable for many more women (n=74) and also showed sufficient variation. 
Here the apparent relative risk gradient differed even less from the actual one than was the case for 
total duration of use. It must be noted, however, that the degree of misclassification found In our 
study might easily obliterate a much weaker duration-response relationship than the one 
hypothesized InTableV (e.g.,an “actual” relative risk of 2.0 Instead of 6.0 associated with the longest 
duration of actual OC exposure). 
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The effect of 
cases and 6C 
~isclasslfication of duration of OC use in a hypothetical case-control study with 21A5 
controls and a duration-response gradient with increasing exposure 
Actual situation 
Actual OC &&s “Actual” 
exposure (months) case control RR 
0 A C 1 .o 
l-46 2A 2.0 
49-96 3A 3.0 
97-l 44 4A 4.0 
145-l 92 5A 5.0 
193-240 6A C 6.0 
Total 2iA 
Observed situation* 
6C 
Reported OC 
exposure 
(months) 
cases controls 
“Apparent” 
RR for total 
duration of 
use+ 
“Apparent” 
RR for duration 
of the longest 
oc used# 
0 (1-p)At2qA 
l-48 2(1-p-q)At pAt3qA 
49-96 3(1-p-q)At2pAt4qA 
97-144 4(1-p-q)At3pAt5qA 
145-l 92 5(1-p-q)At4pAtGqA 
193-240 6(1-q)At5pA 
RR = relative risk estimated as odds ratio 
1.0 1.0 
(I-p)E+qC 1.4 1.6 
C 2.2 2.7 
: 2.7 3.7 
3.4 4.7 
(l-q)C+pC 4.4 5.9 
§ A = number of cases and C = number of controls, who were actually not exposed to OC 
* Calculations according to Marshall u (6) 
p = proportion of subjects whose exposure is overstated 
q = proportion of subjects whose exposure is understated 
t p cases = 0.36, p controls = 0.44, q cases = 0.09, q controls = 0.09 
# p cases = 0.29, p controls = 0.22, q cases = 0.06, q controls = 0.04 
Factors affectina aareement 
InTable VI results are reported of a multiple linear regression analysis in which the potential 
effects of age, socioeconomic status and case-control status on agreement levels were examined. 
Besides these user characteristics, we also investigated recall period (i.e. period over which a woman 
has to recall her OC use) and the sequence of use (Le. whether a specific preparation was used as 
the first or latest OC, or in between). 
An interesting finding is that women of medium and high socioeconomic status agreed better 
with prescribers on both brand names and dates of usage than women of low socioeconomic status. 
A woman’s age and her case-control status did not significantly affect agreement, although cases 
tended to show higher agreement on brand names than controls. Further, the recall period was 
found to affect agreement on stopping dates and brand names. Agreement was significantly less 
when the period of pill use was in the more distant past. With recall period taken into account, there 
was little difference in agreement between the first and the latest OC used. A general tendency was 
noted for intermediate pills to show less agreement han first or latest used preparations. 
Because of concern for the non-independence of agreement on usage of different OC’s taken 
by the same woman, the analyses were run separately for women who used one pill only. Again, 
recall period and socioeconomic class clearly emerged as significant effects. 
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Table 
Multiple regression models with agreement on brand names,startlng dates and stopping dates as dependent 
varhbles 
Variable 
Intercept 
Agreement on Agreement on Agreement on 
brand names starting stopping 
(n=t78) dates (n = 169) dates (n = 179) 
B+SE’* p value B’+SE” p value B’~SE’* p value 
0.54 7.02 51.2 
Recall period*** -1.23.10’3 
+6.70.10+ 0.07 -0.03 * 0.05 0.51 -0.11 to.03 0.0015 
OC sequence+ 
- latest 0.03~0.10 0.74 5.24t6.09 0.39 -3.21 k5.43 0.56 
- intermediate 0.15to.io 0.16 11.7Ok6.10 0.06 5.78e5.41 0.29 
Socioeconomfc 
status+ + 
- medium 0.03+0.08 0.66 -1096~5.11 0.05 -7.01 55.41 0.09 
- high -0.16+0.09 0.09 -11.34k5.91 0.06 -8.58r4.78 0.07 
Case-control 
status+ + + -0.08~0.07 0.25 2.91+4.60 0.53 -1.87~3.81 0.62 
Age 5.p.10 -4t4.7.10 
-5 0.92 0.43?0.32 
R =0.08 Fl*=0.09 
0.18 _0207?0.25 0.77 
R =0.14 
l 
t. 
l ** 
+ 
++ 
+++ 
O=months difference between user and prescrfber per unit change In variable 
SE. standard error 
Recall period. defined as the dgference in months between date at Interview and stopping date for the 
models with agreement on brand names and stcpplng dates as dependent variables; defined as the 
dUference In months between date at Interview and starting date for the model with agreement on starting 
date as dependent varfable 
Reference category: ftrst OC used 
Reference category: low socioeconomic status 
Reference category: controls 
Diiuseion 
A major problem in validity studies on women’s recall of OC use is that the absolute truth is 
unknown. Accuracy of recall is generally measured through agreement between the women’s 
recalled OC use and prescriber records. This is an imperfect approach for several reasons. Firstly, 
not one study, this one Inciuded,checked prescriber records for women who reported no history of 
OC use. Although OC use is not likely to be forgotten by a woman, ft cannot be ruled out that some 
women may be unwilling to report a history of very early OC use. Secondly, prescribers may be a 
less reliable source of information on dates of usage, as it is not uncommon for women to stop OC 
use without notifylng their physician. Thirdly, prescriber records are often incomplete and, as a 
consequence, agreement can only be calculated for a subset of women. However, we do not believe 
that this is likely to lead to bias in studies like ours where missing prescriber information is not due to 
lack of prescriber collaboration, but to (partial) destruction of archives which often accompanies a 
prescriber’s retirement or death. Fourthly, it is quite common that current prescribers do not have all 
earlier OC use at their disposal. Therefore,we contacted all prescribers mentioned by each woman. 
This approach entails the danger that a woman forgets an early prescriber or thinks that her early OC 
use was prescribed for her by a later prescriber. In such cases, the proportion of agreement reported 
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in the present study is too low. Rosenberg et al. mention a fiih source of potential bias, namely, the 
exclusion from analysis of women who could not remember the names of their prescribers (9). Bias 
would arise if such women were also less likely to remember their OC use. In our study, apparently, 
no women had to be excluded for this reason (i.e., for all preparations recalled, all women could 
recollect the names of the relevant prescribers). It is still possible, however, that some women failed 
to remember a prescriber because they dM not recall the use of the preparation he/she had 
prescribed. Finally, comparing the women’s OC history with prescriber records implies that in all 
validity studies, permission has be sought from the women to approach their prescriber(s). 
Awareness of the fact that OC information will be checked with prescriber information may bring the 
women to more extensfve memory searching. Hence, the accuracy of a woman’s OC information as 
assessed in valldfty studies may have been affected upwardly as compared to studies In which OC 
information is collected solely from the women. 
With the above limitations in mind, it is clear that the results reported here should not be interpreted 
as the absolute validity of OC histories obtained by interview. Rather, we should speak of the relatlve 
validity of recalled OC use, with prescriber records as the only available, but Imperfect, standard for 
measuring validity. Since computerized prescription forms from pharmacies have only become 
avallaMe in The Netherlands in the last few years, this information could not be used as a source of 
comparison with women’s recalled Me-time OC use. 
Table VII lists the results of all OC agreement studies conducted to date. A comparison between our 
results and those of previous studies is difffcult, however, because of differences in study populations 
and methods. Since the agreement studies in the 1970’s were carried out (7-g) the number of OC 
preparations on the market has increased and, even more importantly, the interval between first OC 
use and interview has been substantially extended. Also, our population is considerabfy older than 
that in all other studies. Further, two early studies dfd not yet employ memory aids such as a book of 
OC photographs and a life events calendar (7,6). 
As might be expected from the above considerations, agreement In our study tended to be 
lower than reported in most previous studies (TaMeVIl). However, agreement on formulation-specific 
brand name was certainly not lower than In earlier studies when taking into account that Glass et al. 
and Stolley et al. did not require agreement on dosage (76). 
Also when compared to the recent study by Coulter et al. (10). agreement on dates of usage 
and duration of use seems rather low in the present study. For example, 69% of women interviewed 
with memory aids in the former study, showed agreement on total duration of use to within one year, 
whereas this was only 47% in our study. Higher agreement in the Coulter study may be explained by 
the fact that a different source of comparison was used. The women were participants of the 
prospective cohort study of the Oxford-Family Planning Association and their recalled histories were 
compared wth self-reported histories of actual use as recorded annually during the course of the 
study. The advantage of this approach is that the study did not rely on prescriber’s records of 
sometimes questionable quality. Particularly for stopping dates and, as a consequence, also for the 
duration of use, prescribers may be inaccurate and this would tend to produce lower agreement in 
all studies using prescriber records as compared to Coulter’s study. However, there are also some 
disadvantages to Coulter’s source of comparison: a) the study population was so used to answering 
questions about its OC use that a certain training effect may have taken place, and b) the source of 
comparison for very early OC use was probably also women’s recall, i.e. when they entered the 
cohort at age 25. Both of these disadvantages would also tend to elevate the observed proportion of 
agreement In Coulter’s study. 
We examined the Impact of our rather low agreement on duration of use by computing the 
effect of misclassifications on relative risk estimates in a hypothetical case-control study. Despite 
considerable overstatement of total duration of use by OC users, a woman’s recall was found to be 
accurate enough to examine the presence of a moderately strong duration-response relationshlp. A 
weak duration-response relationship might be masked by the degree of misclassification in our study. 
An important finding is that misclassification of duration was mainly non-differential in our data. A 
negligible degree of differential misclassification was also found in the only other case-control study 
of breast cancer and OC that examined its effect (3). In that study, which was restricted to women 
under age 36, it was calculated that, at most, cases remembered 2% more of their actual OC use 
than did controls. The extent of nondffferential misclassification was not reported, probably because 
of the high degree of incompleteness of prescribers’ records. It was found that both cases and 
controls reported approximately double the use recorded in prescribers’ notes, thus calling into 
question the value of information from prescribers as a validity standard (3). In line with these results, 
Rosenberg et al. did not observe a significant difference between cases of hepatocellular adenoma 
and controls in agreement on total duration of OC use (9). In contrast, Stolley et al. reported 
significantly better agreement on starting date of last OC and duration of use for cases with 
thromboembolic disease as compared to controls. As in our study, Stolley et al. reported that 
overstatement of duration was more common than understatement, but, surprisingly, controls tended 
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Table VII Summary of studies of agreement on OC histories between users and prescribers 
of wblkation) 
characterfstic Glass Smlley Rosenberg Coulter Van Laeuwen 
(1974) (1976) (1963) (1966) (1991) 
Study population 
Year of study 
Aoreement 
Brand name 
latest OC 
Brand name 
Rrst oc 
Starting date 
first OC 
Starting date 
latest OC 
Stopping date 
latest OC 
Total duration 
n.r. 
l 
l * 
l ** 
75 healthy 79 cases of 
women thrombo- 
embolism, 
197 hospftal 
controls 
60% <66yrs 
< 35 yrs (66%c35) 
? 1970-l 973 
79%* 89%* 
74%* n.r 
n.r. n.r. 
61 cases of 
hepetoceilular 
adenoma 
69 healthy 
99 healthy 
women 
71%<35yrs 3541 yrs 
1976 1964 
n.r. 5363% 
nr. 69% 
nr. 
n.r. 
96% 
(* 1 year) 
nr. 
nr. 63-79% 
(* 1 year) 
60%.’ 
(2 1 month) 
5769% 
(* 1 year) 
77%~94% 
(2 2 years) 
127 breast cancer cases 
56 healthy contrds 
33 hospital controls 
< 65 yrs 
(12% < 35 yrs) 
1983-1985 
70% 
n.r. 52% 
(f 1 month) 
n.r. 74% 
(? 1 month) 
80-96%“’ 36% 
(2 1 month) 
77% 
(2 1 year) 
53% 
(+ 1 year) 
49% 
(* 1 year) 
63% 
(* 1 year) 
47% 
(* 1 year) 
59% 
(+ 2 years) 
not reported 
For agreement on brand name,agrsement on correct &66g6 was not required 
Agreement calculated In a different way, I.e., number of months for which the women’s 
OC history agreed with her prescriber’s, dh4ded by the total number of months of OC 
use recallsd by the woman. This method may aaslly lead to artffichlly high agreement. 
Estimated by Rosenberg et al. from a scattergram presented by Glass et al. 
to overestimate their OC use even more than cases. A limitation in our design, and also in Stolley’s, 
is that the control group differs from the typical population-based control groups used in many case- 
control studies. However, it is not very likely that our controls had given more thought to their OC 
use than a randomly selected population-based sample. For the hospital controls, who constituted 
36% of our control group, a biopsy for benign breast disease had been performed 5 years or longer 
ago. 
We did observe a case-control difference In agreement on brand names. Breast cancer 
patients showed higher agreement than controls, although the difference was not significant (74% vs 
65%). A similar result was described by Rosenberg et al., but Stolley et al. did not observe case- 
control differences in agreement on brand name. 
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Coulter et al. reported that the first pill (both name and commencement of use) was better 
remembered than any later pills (10). This finding may bs attributed to the greater signkicance for a 
woman of her first OC and its frequent relation to well-remembered life events such as marriage (IO). 
We are not able to corroborate this result, although the fkst pill was certainly not remembered any 
less well than later pills. This Is, In itself, rather remarkable when seen In the light of the long recall 
period In our study. Wlth recall period adjusted for in a muftivarlate analysis, agreement on both 
brand name and starting date of the first OC was even slightly higher than that for the latest OC. 
Therefore, the difference between Coulter’s study and the one presented here may also be explained 
by a longer recall perfod In our study. 
This study was also set up to test the feasibility of obtainlng information on OC use from 
prescribers. Although prescrfber collaboration was very hlgh (94%) usable OC Information was only 
obtained for 48% of OC preparations mentloned by the women. Complete information was only 
obtalned for 34% of all preparations. It can be conduded.therefore.that prescriber records cannot be 
used as the sate data source in a case-contrd study. However, we found prescriber records to be 
extremely useful for supplementing women’s OC histories, particularly regarding specific brand 
names and stopplng dates connected to a change of contraceptive method (I.e. sterilization, Insertion 
of intrauterine device and vasectomy). In the ongoing case-control study of breast cancer risk and 
OC use,lt was,therefore,dedded to collect Information on OC use from both the women and their 
prescribers. Decision rules have been estabfished to sort out, in case of conflicting information from 
user and prescriber, whose report of OC use will be considered to be most correct. 
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